Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies

Expert Opinion on Drug Discovery

Volumn 8, Issue 6, 2013, Pages 621-640

  Matthews, Thomas P ^a   Jones, Alan M ^a   Collins, Ian ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Cancer; Cell cycle checkpoint; DNA damage; Kinase inhibitor; Structure based drug design

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; 7 HYDROXYSTAUROSPORINE; CCT 241533; CISPLATIN; CYTARABINE; EXEL 9844; FLUOROURACIL; GDC 0425; GDC 0575; GEMCITABINE; INDAZOLE DERIVATIVE; LY 2606368; PEMETREXED; PF 00477736; PHOSPHOTRANSFERASE INHIBITOR; PV 1019; PYRAZINE DERIVATIVE; RABUSERTIB; SAR 020106; SCH 900776; TOPOTECAN; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VRX 0466617; XL 844;

ACUTE LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL MEMBRANE PERMEABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CRYSTAL STRUCTURE; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; FLUORINATION; G2 PHASE CELL CYCLE CHECKPOINT; HEAD AND NECK CANCER; HUMAN; HYDROGEN BOND; IC 50; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; METASTATIC MELANOMA; NEOPLASM; NONHUMAN; ONCOGENE C MYC; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THYMOCYTE; UTERINE TUBE CARCINOMA; X RAY CRYSTALLOGRAPHY;

CELL CYCLE CHECKPOINTS; CHECKPOINT KINASE 2; DATABASES, PROTEIN; DNA DAMAGE; DRUG DESIGN; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 84877974285     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.788496     Document Type: Review

References (106)

1. Chen T, Stephens PA, Middleton FK, Curtin NJ. Targeting the S and G2 checkpoint to treat cancer. Drug Discov Today 2012;17:194-202
2. Garrett MD, Collins I. Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci 2011;32:308-16
3. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011;17:88-96
4. Maugeri-Sacca M, Bartucci M, De Maria R. Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. Cancer Treat Rev 2012.Available from: http://dx.doi.org/ 10.1016/j.ctrv.2012.10.007
5. Janetka JW, Ashwell S, Zabludoff S, Lyne P. Inhibitors of checkpoint kinases: from discovery to the clinic. Curr Opin Drug Discov Dev 2007;10:473-86
6. Lainchbury M, Collins I. Checkpoint kinase inhibitors: a patent review (2009 - 2010). Expert Opin Ther Pat 2011;21:1191-210
7. Prudhomme M. Novel checkpoint 1 inhibitors. Recent Pat Anti Cancer Drug Discov 2006;1:55-68
8. Nguyen TN, Tepe JJ. Current inhibitors of checkpoint kinase 2. Curr Med Chem 2011;18:4368-74
9. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: chk1, Chk2, and MK2. Curr Opin Cell Biol 2009;21:245-55
10. Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010;108:73-112
11. Antoni L, Sodha N, Collins I, Garrett MD. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nat Rev Cancer 2007;7:925-36
12. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010;16:376-83
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
14. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53
15. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999;274:36031-4
16. Zabludoff SD, Deng C, Grondine MR, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008;7:2955-66
17. Guzi TJ, Paruch K, Dwyer MP, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther 2011;10:591-602
18. Walton MI, Eve PD, Hayes A, et al. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther 2010;9:89-100
19. Blasina A, Hallin J, Chen E, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 2008;7:2394-404
20. Walton MI, Eve PD, Hayes A, et al. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin Cancer Res 2012;18:5650-61
21. Tse AN, Rendahl KG, Sheikh T, et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res 2007;13:591-602
22. Brooks K, Oakes V, Edwards B, et al. A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress. Oncogene 2012;published online 5 March 2012; doi:10.1038/onc.2012.72
23. Cavelier C, Didier C, Prade N, et al. Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. Cancer Res 2009;69:8652-61
24. Conti C, Seiler JA, Pommier Y. The mammalian DNA replication elongation checkpoint: implication of Chk1 and relationship with origin firing as determined by single DNA molecule and single cell analyses. Cell Cycle 2007;6:2760-7
25. Hoglund A, Nilsson LM, Muralidharan SV, et al. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin Cancer Res 2011;17:7067-79
26. Anderson VE, Walton MI, Eve PD, et al. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res 2011;71:463-72
27. Converso A, Hartingh T, Garbaccio RM, et al. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg Med Chem Lett 2009;19:1240-4
28. Vanderpool D, Johnson TO, Ping C, et al. Characterization of the CHK1 allosteric inhibitor binding site. Biochemistry 2009;48:9823-30
29. Chen P, Luo C, Deng Y, et al. The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1: implications for Chk1 regulation. Cell 2000;100:681-92
30. Oza V, Ashwell S, Almeida L, et al. Discovery of checkpoint kinase inhibitor (S)-5-(3-Fluorophenyl)-N-(piperidin-3- yl)-3-ureidothiophene-2- carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas. J Med Chem 2012;55:5130-42
31. Janetka JW, Almeida L, Ashwell S, et al. Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors. Bioorg Med Chem Lett 2008;18:4242-8
32. Zhao L, Zhang Y, Dai C, et al. Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors. Bioorg Med Chem Lett 2010;20:7216-21
33. Oza V, Ashwell S, Brassil P, et al. Discovery of a novel class of triazolones as checkpoint kinase inhibitors-hit to lead exploration. Bioorg Med Chem Lett 2010;20:5133-8
34. Oza V, Ashwell S, Brassil P, et al. Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors. Bioorg Med Chem Lett 2012;22:2330-7
35. Zuccotto F, Ardini E, Casale E, Angiolini M. Through the "gatekeeper door": exploiting the active kinase conformation. J Med Chem 2010;53:2681-94
36. Foloppe N, Fisher LM, Francis G, et al. Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification. Bioorg Med Chem 2006;14:1792-804
37. Fraley ME, Steen JT, Brnardic EJ, et al. 3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: optimization of potency and selectivity via substitution at C6. Bioorg Med Chem Lett 2006;16:6049-53
38. Tao Z-F, Wang L, Stewart KD, et al. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. J Med Chem 2007;50:1514-27
39. Vernalis Oncology pipeline - V158411. Available from: http://www.vernalis.com/ development/nce-pipeline [Last accessed 28th January 2013]
40. Massey AJ, Stokes S, Browne H, et al. Abstract C207: Checkpoint abrogation and potentiation of cytotoxic chemotherapeutics with a novel checkpoint kinase 1 inhibitor. AACRNCI- EORTC International Conference: Molecular Targets and Cancer Therapeutics. 15-19 Nov 2009; Boston, MA. Mol Canc Ther 2009. 8:C207
41. Li G, Hasvold LA, Tao Z-F, et al. Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5- cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors. Bioorg Med Chem Lett 2006;16:2293-8
42. Matthews TP, Klair S, Burns S, et al. Identification of inhibitors of checkpoint kinase 1 through template screening. J Med Chem 2009;52:4810-19
43. Matthews TP, McHardy T, Klair S, et al. Design and evaluation of 3,6-di (hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases. Bioorg Med Chem Lett 2010;20:4045-9
44. Reader JC, Matthews TP, Klair S, et al. Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing. J Med Chem 2011;54:8328-42
45. Borst GR, McLaughlin M, Kyula JN, et al. Targeted radiosensitization by the Chk1 Inhibitor SAR-020106. Int J Radiat Oncol Biol Phys 2012;published online 4 September 2012; doi:10.1016/j.ijrobp.2012.08.006
46. Lainchbury M, Matthews TP, McHardy T, et al. Discovery of 3- alkoxyamino-5-(pyridin-2-ylamino) pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. J Med Chem 2012;55:10229-40
47. Dwyer MP, Paruch K, Labroli M, et al. Discovery of pyrazolo[1,5-a] pyrimidinebased CHK1 inhibitors: a template-based approach-part 1. Bioorg Med Chem Lett 2011;21:467-70
48. Montano R, Chung I, Garner K, et al. Preclinical development of the novel Chk1 Inhibitor SCH900776 in combination with DNA damaging agents and antimetabolites. Mol Cancer Ther 2011;427-38
49. Huang X, Cheng CC, Fischmann TO, et al. Discovery of a novel series of CHK1 kinase inhibitors with a distinctive hinge binding mode. ACS Med Chem Lett 2012;3:123-8
50. Dudkin VY, Rickert K, Kreatsoulas C, et al. Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates. Bioorg Med Chem Lett 2012;22:2609-12
51. Dudkin VY, Wang C, Arrington KL, et al. Pyridyl aminothiazoles as potent Chk1 inhibitors: optimization of cellular activity. Bioorg Med Chem Lett 2012;22:2613-19
52. Hilton S, Naud S, Caldwell JJ, et al. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2. Bioorg Med Chem 2010;18:707-18
53. Curman D, Cinel B, Williams DE, et al. Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J Biol Chem 2001;276:17914-19
54. Caldwell JJ, Welsh EJ, Matijssen C, et al. Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2. J Med Chem 2011;54:580-90
55. Matijssen C, Silva-Santisteban MC, Westwood IM, et al. Benzimidazole inhibitors of the protein kinase CHK2: clarification of the binding mode by flexible side chain docking and protein-ligand crystallography. Bioorg Med Chem 2012;20:6630-9
56. Lountos GT, Tropea JE, Zhang D, et al. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor. Protein Sci 2009;18:92-100
57. Lountos GT, Jobson AG, Tropea JE, et al. Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy. J Struct Biol 2011;176:292-301
58. Jobson AG, Cardellina JH, Scudiero D, et al. Identification of a Bis-guanylhydrazone [4,4¢- Diacetyldiphenylurea-bis (guanylhydrazone); NSC 109555] as a Novel Chemotype for Inhibition of Chk2 Kinase. Mol Pharmacol 2007;72:876-84
59. Jobson AG, Lountos GT, Lorenzi PL, et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1Hindole- 2-carboxylic acid f4-[1- (guanidinohydrazone)-ethyl]-phenyl}- amide]. J Pharmacol Exp Ther 2009;331:816-26
60. Arienti KL, Brunmark A, Axe FU, et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem 2005;48:1873-85
61. Neff DK, Lee-Dutra A, Blevitt JM, et al. 2-Aryl benzimidazoles featuring alkyl-linked pendant alcohols and amines as inhibitors of checkpoint kinase Chk2. Bioorg Med Chem Lett 2007;17:6467-71
62. McClure KJ, Huang L, Arienti KL, et al. Novel non-benzimidazole Chk2 kinase inhibitors. Bioorg Med Chem Lett 2006;16:1924-8
63. Oliver AW, Paul A, Boxall KJ, et al. Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. EMBO J 2006;25:3179-90
64. Sharma V, Tepe JJ. Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg Med Chem Lett 2004;14:4319-21
65. Saleem RSZ. Lansdell Ta, Tepe JJ. Synthesis and evaluation of debromohymenialdisine-derived Chk2 inhibitors. Bioorg Med Chem 2012;20:1475-81
66. Carlessi L, Buscemi G, Larson G, et al. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 2007;6:935-44
67. Larson G, Yan S, Chen H, et al. Identification of novel, selective and potent Chk2 inhibitors. Bioorg Med Chem Lett 2007;17:172-5
68. Fuse E, Kuwabara T, Sparreboom A, et al. Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol 2005;45:394-403
69. Senderowicz AM. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy. Cancer Chemother Biol Response Modif 2001;19:165-88
70. Stolz A, Ertych N, Bastians H. Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability. Clin Cancer Res 2011;17:401-5
71. Ashwell S, Janetka JW, Zabludoff S. Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opin Investig Drugs 2008;17:1331-40
72. Wu W, Bi C, Bence AK, et al. Abstract 1776: Antitumor activity of Chk1 inhibitor LY2606368 as a single agent in SW1990 human pancreas orthotopic tumor model. AACR 103rd Annual Meeting 2012. 31 Apr - 4 Mar 2012; Chicago, IL. Cancer Res 2012;72(Suppl 1)
73. McNeely SC, Burke TF, DurlandBusbice S, et al. Abstract A108: LY2606368, a second generation Chk1 inhibitor, inhibits growth of ovarian carcinoma xenografts either as monotherapy or in combination with standard-of-care agents. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. 12-16 Nov 2011; San Francisco, CA. Mol Cancer Ther 2011;10(Suppl 1)
74. Calvo E, Richards D, Braiteh F, et al. Abstract A94: Dose determination of LY2603618, a Chk1 inhibitor, administered in combination with gemcitabine in patients with advanced cancer. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. 12 - 16 November 2011; San Francisco, CA. Mol Cancer Ther 2011;10(Suppl 1)
75. Weiss GJ, Donehower RC, Iyengar T, et al. Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. Invest New Drugs 2013;31:136-44
76. Karp JE, Thomas BM, Greer JM, et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor SCH900776 in refractory acute leukemias. Clin Cancer Res 2012;published online 23 October 2012; doi:10.1158/ 078-0432.CCR-12-2442
77. Luo Y, Leverson JD. New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response. Expert Rev Anticancer Ther 2005;5:333-42
78. Maity A, McKenna WG, Muschel RJ. The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol 1994;31:1-13
79. Mitchell JB, Choudhuri R, Fabre K, et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010;16:2076-84
80. Morgan MA, Parsels LA, Zhao L, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010;70:4972-81
81. Yang H, Yoon SJ, Jin J, et al. Inhibition of checkpoint kinase 1 sensitises lung cancer brain metastases to radiotherapy. Biochem Biophys Res Commun 2011;406:53-8
82. Seol HJ, Yoo HY, Jin J, et al. The expression of DNA damage checkpoint proteins and prognostic implication in metastatic brain tumors. Oncol Res 2011;19:381-90
83. Tang Y, Dai Y, Grant S, Dent P. Enhancing CHK1 inhibitor lethality in glioblastoma. Cancer Biol Ther 2012;13:379-88
84. Tang Y, Hamed HA, Poklepovic A, et al. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. Mol Pharmacol 2012;82:322-32
85. Davies KD, Cable PL, Garrus JE, et al. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. Cancer Biol Ther 2011;12:788-96
86. Carrassa L, Chila R, Lupi M, et al. Combined inhibition of Chk1 and Wee1 in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle 2012;11:2507-17
87. Guertin AD, Martin MM, Roberts B, et al. Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition. Cancer Cell Int 2012;12:45
88. Russell MR, Levin K, Rader J, et al. Combination therapy targeting the chk1 and wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Res 2013;73:779-84
89. McNeely S, Conti C, Sheikh T, et al. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle 2010;9:995-1004
90. Davies KD, Humphries MJ, Sullivan FX, et al. Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo. Oncol Res 2011;19:349-63
91. Murga M, Campaner S, Lopez-Contreras AJ, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol 2011;18:1331-5
92. Cole KA, Huggins J, Laquaglia M, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci USA 2011;108:3336-41
93. Ferrao PT, Bukczynska EP, Johnstone RW, McArthur GA. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 2012;31:1661-72
94. Nguyen TNT, Saleem RSZ, Luderer MJ, et al. Radioprotection by hymenialdisinederived checkpoint kinase 2 inhibitors. ACS Chem Biol 2012;7:172-84
95. Morgan MA, Parsels LA, Parsels JD, et al. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 2006;5:1983-8
96. Xiao Z, Xue J, Sowin TJ, Zhang H. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther 2006;5:1935-43
97. Azorsa DO, Gonzales IM, Basu GD, et al. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med 2009;7:43
98. Ho AL, Bendell JC, Cleary JM, et al. Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors. J Clin Oncol 2011;29:3033
99. Sausville EA, LoRusso P, Carducci MA, et al. Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors. J Clin Oncol 2011;29:3058
100. Fracasso PM, Williams KJ, Chen RC, et al. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol 2011;67:1225-37
101. Li T, Christensen SD, Frankel PH, et al. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Invest New Drugs 2012;30:741-8
102. Kummar S, Gutierrez ME, Gardner ER, et al. A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. Cancer Chemother Pharmacol 2010;65:383-9
103. Ma CX, Ellis MJ, Petroni GR, et al. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat 2013;137:483-92
104. PF-00477736 is being studied in advanced solid tumors in combination with chemotherapy with gemcitabine. Available from: http://clinicaltrials.gov/ ct2/show/results/NCT00437203 [Last accessed 24 January 2013]
105. Array BioPharma, Inc. Checkpoint kinase 1 inhibitors for potentiating the effect of DNA damaging agents in treatment of cancer. WO2010118390; 2010
106. Targeting Checkpoint Kinase 1: a study in the application of preclinical data to inform clinical strategy. Presentation for the 2nd Annual Cancer Targets & Therapeutics Conference 10/21/2010. Available from: http://www. arraybiopharma.com/-documents/ Publication/PubAttachment410.pdf [Last accessed 28 January 2013]